The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Progression-free Survival
Timeframe: 3 months after MR-Linac treatment
Progression-free Survival
Timeframe: 6 months after MR-Linac treatment
Progression-free Survival
Timeframe: 24 months after MR-Linac treatment
Survival
Timeframe: 3 months after MR-Linac treatment
Survival
Timeframe: 6 months after MR-Linac treatment
Survival
Timeframe: 24 months after MR-Linac treatment
Disease-free Survival
Timeframe: 3 months after MR-Linac treatment
Disease-free Survival
Timeframe: 6 months after MR-Linac treatment
Disease-free Survival
Timeframe: 24 months after MR-Linac treatment
Patient reported Health related quality of life (HRQoL).
Timeframe: 3 months after treatment.
Patient reported Health related quality of life (HRQoL).
Timeframe: 6 months after treatment.
Patient reported Health related quality of life (HRQoL).
Timeframe: 12 months after treatment.
Patient reported Health related quality of life (HRQoL).
Timeframe: 24 months after treatment.
Patient reported Health related quality of life (HRQoL).
Timeframe: 3 months after treatment.
Patient reported Health related quality of life (HRQoL).
Timeframe: 6 months after treatment.
Patient reported Health related quality of life (HRQoL).
Timeframe: 12 months after treatment.
Patient reported Health related quality of life (HRQoL).
Timeframe: 24 months after treatment.
Patient reported tumor specific quality of life (QoL).
Timeframe: 3 months after treatment.
Patient reported tumor specific quality of life (QoL).
Timeframe: 6 months after treatment.
Patient reported tumor specific quality of life (QoL).
Timeframe: 12 months after treatment.
Patient reported tumor specific quality of life (QoL).
Timeframe: 24 months after treatment.
Acute toxicity in common toxicity criteria for adverse events (CTCAE).
Timeframe: 3 months after treatment.
Acute toxicity in common toxicity criteria for adverse events (CTCAE).
Timeframe: 6 months after treatment.
Acute toxicity in common toxicity criteria for adverse events (CTCAE).
Timeframe: 12 months after treatment.
Acute toxicity in common toxicity criteria for adverse events (CTCAE).
Timeframe: 24 months after treatment.
Clinical tumor response.
Timeframe: 2 year follow up.
Pathological tumor response.
Timeframe: 2 year follow up.
Toxicity in common toxicity criteria for adverse events (CTCAE).
Timeframe: 2 years